

**Manuscript Title:** Write The Title of Manuscript.

<sup>1</sup>First Author Name, Designation, Name of Department, Name of College and University, Name of City and Country.

<sup>2</sup>Second Author Name, Designation, Name of Department, Name of College and University, Name of City and Country.

<sup>3</sup>Third Author Name, Designation, Name of Department, Name of College and University, Name of City and Country.

<sup>4</sup>.....

<sup>5</sup>.....

**Corresponding Author:** Name of Author, Designation, Name of Department, Name of College and University, Name of City and Country.

**Open Access Article:** © 2026, First Author, et al. This is an open access journal and article distributed under the terms of the creative common's attribution license (<http://creativecommons.org/licenses/by/4.0>). Which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**E-Mail Id:** [abcd0101@gmail.com](mailto:abcd0101@gmail.com)

**Conflicts of Interest:** None

---

## Abstract

**Introduction:** The context and purpose of the study.

**Aim/Objectives:** The aim, design and setting of the study.

**Material and Methods:** How the study was performed and statistical tests used.

**Result:** The main findings in research.

**Discussion:** This section should discuss the implications of the findings in context of existing research and highlight limitations of the study.

**Conclusion:** Write brief summary and potential implications.

**Keywords:** Write five to six keywords representing the main content of the article.

---

## Introduction

In this Introduction section should explain the background to the study, (that is, the nature of the problem and its significance). Its aims, and a summary of the existing literature and why this study was necessary or its contribution to the field.

---

## Material and Method

In this methods section should be includes:

**Study Design:**.....

**Study Duration:**.....

**Study Place:**.....

**Sample Size:**.....

- The characteristics of participants such as:

**Inclusion Criteria:**.....

**Exclusion Criteria:**.....

- Description of materials
- A clear description of all processes, interventions and comparisons.
- Generic drug names should generally be used.
- The detailed experimental protocols, instruments and software etc. used in the study should be describe here with their proper references. The details of the study area should also be provided.

### **Statistical analysis**

The type of statistical analysis used, including a power calculation if appropriate.

### **Results**

In this section, should be include the findings of the study including, if appropriate, results of statistical analysis which must be included either in the text or as tables, graphs, flow charts, figures and all necessary pictures.

### **Discussion**

In this section should be discuss the implications of the findings in context of existing research and highlight limitations of the study.

### **Conclusions**

In this section should state clearly the main conclusions and provide an explanation of the importance and relevance of the study.

### **Declarations**

All manuscripts must contain the following sections under the heading 'Declarations':

- Ethics approval and consent to participate
- Consent for publication
- Authors' contributions
- Acknowledgements

### **References**

1. Mueller C, Giannitsis E, Jaffe AS, Huber K, Mair J, Cullen L, et al. Cardiovascular biomarkers in patients with COVID-19. *Eur Heart J Acute Cardiovasc Care* 2021; 10:310-9.
2. Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. *J Cardiovasc Transl Res* 2020; 13:431-50.
3. Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JG, Coats AJ, et al. Circulating heart failure biomarkers beyond natriuretic peptides: Review from the biomarker study group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). *Eur J Heart Fail* 2021; 23:1610-32.
4. Moura B, Aimo A, Al-Mohammad A, Flammer A, Barberis V, Bayes-Genis A, et al. Integration of imaging and circulating biomarkers in heart failure: A consensus document by the Biomarkers and imaging study groups of the heart failure association of the European Society of Cardiology. *Eur J Heart Fail* 2021; 23:1577-96.
5. Jaffe AS, Lindahl B, Giannitsis E, Mueller C, Cullen L, Hammarsten O, et al. ESC study group on cardiac biomarkers of the association for acute cardiovascular care: A fond farewell at the retirement of CKMB. *Eur Heart J* 2021; 42:2260-4.
6. ....
7. ....
8. ....
9. ....
10. ....